DK1244614T3 - Tryptase-inhibitorer - Google Patents

Tryptase-inhibitorer

Info

Publication number
DK1244614T3
DK1244614T3 DK00990777T DK00990777T DK1244614T3 DK 1244614 T3 DK1244614 T3 DK 1244614T3 DK 00990777 T DK00990777 T DK 00990777T DK 00990777 T DK00990777 T DK 00990777T DK 1244614 T3 DK1244614 T3 DK 1244614T3
Authority
DK
Denmark
Prior art keywords
tryptase inhibitors
inhibitors
tryptase
meanings
compounds
Prior art date
Application number
DK00990777T
Other languages
English (en)
Inventor
Thomas Baer
Josef Stadlwieser
Karl Zech
Thomas Martin
Wolf-Ruediger Ulrich
Andreas Dominik
Daniela Bundschuh
Christian Sommerhoff
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Application granted granted Critical
Publication of DK1244614T3 publication Critical patent/DK1244614T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK00990777T 1999-12-20 2000-12-16 Tryptase-inhibitorer DK1244614T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99125382 1999-12-20

Publications (1)

Publication Number Publication Date
DK1244614T3 true DK1244614T3 (da) 2004-09-27

Family

ID=8239660

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00990777T DK1244614T3 (da) 1999-12-20 2000-12-16 Tryptase-inhibitorer

Country Status (13)

Country Link
US (1) US6815557B2 (da)
EP (1) EP1244614B1 (da)
JP (1) JP2003518087A (da)
AT (1) ATE268322T1 (da)
AU (1) AU783371B2 (da)
CA (1) CA2392127A1 (da)
DE (1) DE60011300T2 (da)
DK (1) DK1244614T3 (da)
ES (1) ES2222270T3 (da)
PT (1) PT1244614E (da)
SI (1) SI1244614T1 (da)
TR (1) TR200402164T4 (da)
WO (1) WO2001046128A2 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1358182T3 (da) 2001-01-31 2004-12-20 Altana Pharma Ag Diazocin-derivater og anvendelsen deraf som tryptase-inhibitorer
ES2287268T3 (es) 2001-02-21 2007-12-16 Nycomed Gmbh Inhibidores de triptasa.
EP1368317B1 (en) 2001-02-21 2006-12-27 Altana Pharma AG Tryptase inhibitors
JP2004525926A (ja) * 2001-03-15 2004-08-26 アルタナ　ファルマ　アクチエンゲゼルシャフト トリプターゼ阻害剤
WO2002074732A2 (en) * 2001-03-15 2002-09-26 Altana Pharma Ag Tryptase-inhibitors
WO2002102771A1 (en) 2001-06-19 2002-12-27 Altana Pharma Ag Tryptase inhibitors
GB0507577D0 (en) * 2005-04-14 2005-05-18 Novartis Ag Organic compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3999946A (en) * 1976-02-23 1976-12-28 Allied Chemical Corporation Time-temperature history indicators
US4228126A (en) * 1977-11-25 1980-10-14 Allied Chemical Corporation Diacetylene time-temperature indicators
WO1995032945A1 (en) 1994-06-01 1995-12-07 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell mediated conditions
WO1996009297A1 (en) 1994-09-23 1996-03-28 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell inflammatory condition
HUP0003267A3 (en) 1996-07-30 2002-02-28 Arris Pharmaceutical Corp San Heteroaryl derivatives, pharmaceutical compositions containing them and process for producing them
AU8997498A (en) 1997-09-05 1999-03-29 Yoshitomi Pharmaceutical Industries, Ltd. Tryptase inhibitor
EP1030844A1 (en) 1997-11-10 2000-08-30 Array Biopharma Inc. Compounds which inhibit tryptase activity
US6221914B1 (en) * 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
ATE282607T1 (de) 1998-02-06 2004-12-15 Max Planck Gesellschaft Tryptase-inhibitoren
JP2002502845A (ja) * 1998-02-06 2002-01-29 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ トリプターゼ阻害物質
WO2000014097A2 (de) 1998-09-04 2000-03-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue pyranosen
SI1208089T1 (en) 1999-08-10 2005-04-30 Altana Pharma Ag Diazocin-dione derivatives and their use as tryptase inhibitors
WO2001019809A1 (en) 1999-09-14 2001-03-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Tryptase inhibitors

Also Published As

Publication number Publication date
ATE268322T1 (de) 2004-06-15
AU3013101A (en) 2001-07-03
SI1244614T1 (en) 2004-10-31
JP2003518087A (ja) 2003-06-03
EP1244614B1 (en) 2004-06-02
CA2392127A1 (en) 2001-06-28
AU783371B2 (en) 2005-10-20
ES2222270T3 (es) 2005-02-01
DE60011300T2 (de) 2005-08-04
US6815557B2 (en) 2004-11-09
WO2001046128A2 (en) 2001-06-28
EP1244614A2 (en) 2002-10-02
DE60011300D1 (de) 2004-07-08
PT1244614E (pt) 2004-10-29
WO2001046128A3 (en) 2001-11-22
TR200402164T4 (tr) 2004-10-21
US20030073720A1 (en) 2003-04-17

Similar Documents

Publication Publication Date Title
PL372926A1 (en) Piperidine-pyridazones and phthalazones as pde4 inhibitors
DE60310576D1 (en) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
ES2186874T3 (es) Analogos de m-amidinofenilo como inhibidores del factor xa.
DK1070056T3 (da) Phthalazinon-PDE III/IV-inhibitorer
TR200200883T2 (tr) 2-ikameli 1,1-bifenil-2-karbonamidler, imalat yöntemleri, ilaç olarak kullanılmaları
YU19499A (sh) Benzonaftiridini kao bronhijalni terapeutici
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
BR0007922A (pt) Compostos calcilìticos
SE9903290D0 (sv) Novel compounds
DK1244643T3 (da) Tryptaseinhibitorer
DK1204659T3 (da) Serotonerge benzofuraner
ATE287403T1 (de) 6-phenylbenzonaphthyidine
BRPI0415285A (pt) derivados de aminoalcanol
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
DK1244614T3 (da) Tryptase-inhibitorer
DE60216920D1 (en) Tryptase-inhibitoren
ATE213236T1 (de) Substituierte benzyloxyimino-verbindungen
ATE364037T1 (de) Tryptasehemmer
ATE491709T1 (de) Pyrrolidinohydrochinazoline
DE60120398D1 (de) Imidazopyridin-8-one
SI1358182T1 (en) Diazocine derivates and their use as tryptase inhibitors
AU758194C (en) Novel benzimidazoles and benzoxazoles
ATE349427T1 (de) Tryptaseinhibitoren
SG145572A1 (en) Intermediates useful in the synthesis of hiv-protease inhibitors and methods for preparing the same